1000 usd to cad

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Independent sales representatives provide scalable technology sales opportunity for health screening and vaccine passports to Contakt World and its portfolio companies

  • HealthCheck's existing 1,000+ customer sites were acquired through sales efforts of one part-time independent sales representative and two founders leading to $1.55M CAD revenue and $555K CAD net profit for the twelve-months ended July 31, 20211
  • In addition to plans to bolster its revenue opportunities with vaccine passports and validation, Contakt World just launched a program to aggressively add independent sales representatives to scale sales within employer establishments, K-12 schools and event venues in the US
  • Contakt World's advertisements and initial screening process to add independent sales representatives for health screening, vaccine passports, and future solutions yielded dozens of qualified applicants in less than two weeks
  • Independent sales representatives are expected to grow customer base and increase revenue for HealthCheck and future solutions like vaccine passports on a commission-only basis

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges like symptom screening and vaccine passports, today announced it will create a network of independent sales representatives to scale sales for the recently acquired HealthCheck app, vaccine passports, and future acquisitions or partnering products.

Contakt World's processes for independent sales representatives are being designed for efficient onboarding, CRM to track leads and sales, recurring trainings, and lead generation to support independent sales representatives. Independent sales representatives will be paid a commission of 10% on their collected sales from health screening, vaccine passports, and future products.

"A single independent sales representative working on a commission-basis led to hundreds of commercial users for HealthCheck and 12-month trailing revenues of $1.55M CAD1, as at July 31, 2021, before we acquired the company," stated Justin Beck, Chief Visionary Officer for Contakt World. "HealthCheck is an attractive solution for organizations of all shapes and sizes, where liabilities relating to COVID-19, vaccine passports, symptom screening, and safety are reduced through our SaaS solutions. More independent representatives to sell our solutions means more sales opportunities for Contakt World." Contakt has initiated the onboarding of several sales representatives with the goal of contracting a team of 15-20 people in the next 30-60 days distributed across multiple states in the United States.

In addition to its efforts to add vaccine credentials and vaccine validation to the HealthCheck screening tool, Contakt World is negotiating with several partner technologies to bolster its SaaS portfolio for customers in a number of health-related fields. Symptom screening, vaccine passports, vaccine validation, and other methods to improve population safety and reduce liability are becoming key to everyday business, travel, and social life.

Other Recent Related News from Contakt World:

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

To Learn More:

To receive investor updates from Contakt World Technologies Corp. including its efforts in the field of vaccine passports, click here.

If you are an organization seeking daily health screening and future vaccine passports, schedule a demo of HealthCheck by clicking here.

About Contakt World

Contakt World's mission is to develop or acquire and deliver software (SaaS) that improves access to, efficiencies within, and quality of healthcare in all its forms. Contakt World envisions a world where everyone can achieve their full health potential, and no one is disadvantaged from achieving this potential because of social position or other circumstances. Contakt World's portfolio presently includes the award-winning software platform, Smart Health RM, and HealthCheck by Stratum which is used in over 1,000 locations. For more information, please visit https://contakt.world/.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: Healthcheck's integration into Contakt World's offerings, business plan and growth strategy; Healthchecks's prospects as a platform and service; Contakt World's ability to scale and sell HealthCheck, including through its new sales representative program; Contakt Worlds's work to bolster its SaaS portfolio; Contakt World's ability to deploy a successful vaccine passport; and Contakt World's ability to leverage Healthcheck going forward. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

____________________

1 Unaudited, based on management prepared financial information for the 12-months ending July 31,2021 using 1 USD to 1.26 CAD exchange rate on August 31, 2021.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95097

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×